[Clinical and immunological effectiveness of prodigiozan in suppurative surgical diseases].
D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000992:Antitoxins / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D003168:Complement Fixation Tests; D003864:Depression, Chemical; D006801:Humans; D007223:Infant; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D010587:Phagocytosis / Q000187:drug effects*; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use*; D012706:Serratia marcescens; D013208:Staphylococcal Toxoid / Q000097:blood*; D013210:Staphylococcus; D013268:Stimulation, Chemical; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000276:immunology; D014945:Wound Healing / Q000187:drug effects
D000906:Antibodies; D000970:Antineoplastic Agents; D000992:Antitoxins; D001798:Blood Proteins; D011135:Polysaccharides, Bacterial; D013208:Staphylococcal Toxoid; D002097:C-Reactive Protein
Klinicheskaia i immunologicheskaia éffektivnost' prodigiozana pri gnoĭnykh khirurgicheskikh zabolevaniiakh.